JPS5823382B2 - 2-Aminoacetamide-alpha-phenylbenzylidene aminoalkanol - Google Patents
2-Aminoacetamide-alpha-phenylbenzylidene aminoalkanolInfo
- Publication number
- JPS5823382B2 JPS5823382B2 JP50008503A JP850375A JPS5823382B2 JP S5823382 B2 JPS5823382 B2 JP S5823382B2 JP 50008503 A JP50008503 A JP 50008503A JP 850375 A JP850375 A JP 850375A JP S5823382 B2 JPS5823382 B2 JP S5823382B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- reaction
- general formula
- formula
- phenylbenzylidene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 46
- -1 2-aminoacetamido-α-phenylbenzylidene Chemical group 0.000 claims description 33
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 125000006239 protecting group Chemical group 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 26
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 239000002904 solvent Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 6
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 229910052783 alkali metal Inorganic materials 0.000 description 5
- 150000001340 alkali metals Chemical class 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 150000002391 heterocyclic compounds Chemical class 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 4
- 235000015497 potassium bicarbonate Nutrition 0.000 description 4
- 239000011736 potassium bicarbonate Substances 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 3
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- 239000000920 calcium hydroxide Substances 0.000 description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 3
- 150000003512 tertiary amines Chemical class 0.000 description 3
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- FRMJYZMIJTZMMB-UHFFFAOYSA-N C(C)O.C1(CCCCC1)N=C=NC1CCCCC1 Chemical compound C(C)O.C1(CCCCC1)N=C=NC1CCCCC1 FRMJYZMIJTZMMB-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 description 2
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 2
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 229960001269 glycine hydrochloride Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 208000018198 spasticity Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QACUOWCDCMROJT-UHFFFAOYSA-N (2,3,4,5,6-pentachlorophenyl) 2,2,2-trifluoroacetate Chemical compound FC(F)(F)C(=O)OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl QACUOWCDCMROJT-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- ARKIFHPFTHVKDT-UHFFFAOYSA-N 1-(3-nitrophenyl)ethanone Chemical compound CC(=O)C1=CC=CC([N+]([O-])=O)=C1 ARKIFHPFTHVKDT-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- KATCELVJLDODSG-UHFFFAOYSA-N 2-[(2,2,2-trichloroacetyl)amino]acetic acid Chemical compound OC(=O)CNC(=O)C(Cl)(Cl)Cl KATCELVJLDODSG-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- SDXAWLJRERMRKF-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrazole Chemical compound CC=1C=C(C)NN=1 SDXAWLJRERMRKF-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- BUCORZSTKDOEKQ-UHFFFAOYSA-N 7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine Chemical compound C=12C=C(Cl)C=CC2=NC(=NC)CN(O)C=1C1=CC=CC=C1 BUCORZSTKDOEKQ-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 244000186140 Asperula odorata Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 235000008526 Galium odoratum Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- BWFWAOOINUDDNR-UHFFFAOYSA-N [Si]1(ONCC1)=O Chemical compound [Si]1(ONCC1)=O BWFWAOOINUDDNR-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- SLUNEGLMXGHOLY-UHFFFAOYSA-N benzene;hexane Chemical compound CCCCCC.C1=CC=CC=C1 SLUNEGLMXGHOLY-UHFFFAOYSA-N 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FIIIODAHWWIWCY-UHFFFAOYSA-K calcium potassium hydrogen carbonate carbonate Chemical compound [K+].[Ca+2].OC([O-])=O.[O-]C([O-])=O FIIIODAHWWIWCY-UHFFFAOYSA-K 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- TXHWYSOQHNMOOU-UHFFFAOYSA-N chloro(diethoxy)phosphane Chemical compound CCOP(Cl)OCC TXHWYSOQHNMOOU-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- GJAHYSLBRZODMY-UHFFFAOYSA-N dibenzylcyanamide Chemical compound C=1C=CC=CC=1CN(C#N)CC1=CC=CC=C1 GJAHYSLBRZODMY-UHFFFAOYSA-N 0.000 description 1
- RDXABLXNTVBVML-UHFFFAOYSA-N diethoxyphosphanyl diethyl phosphite Chemical compound CCOP(OCC)OP(OCC)OCC RDXABLXNTVBVML-UHFFFAOYSA-N 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- WMYNMYVRWWCRPS-UHFFFAOYSA-N ethynoxyethane Chemical group CCOC#C WMYNMYVRWWCRPS-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 150000002366 halogen compounds Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229940017219 methyl propionate Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- ITYOPMRLCKEGTK-UHFFFAOYSA-N n-ethyl-n-ethynylbutan-2-amine Chemical compound CCC(C)N(CC)C#C ITYOPMRLCKEGTK-UHFFFAOYSA-N 0.000 description 1
- IFTFOOGMLVHUKR-UHFFFAOYSA-N n-ethyl-n-ethynylhexan-2-amine Chemical compound CCCCC(C)N(CC)C#C IFTFOOGMLVHUKR-UHFFFAOYSA-N 0.000 description 1
- ICBREYRCFNVVQS-UHFFFAOYSA-N n-ethyl-n-ethynylpropan-2-amine Chemical compound CCN(C#C)C(C)C ICBREYRCFNVVQS-UHFFFAOYSA-N 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical group [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
- 150000003018 phosphorus compounds Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- UTLZBWAGLRNNAY-UHFFFAOYSA-J thorium(4+);dicarbonate Chemical compound [Th+4].[O-]C([O-])=O.[O-]C([O-])=O UTLZBWAGLRNNAY-UHFFFAOYSA-J 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
- C07C251/24—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【発明の詳細な説明】
本発明は新規な医薬化合物およびその製法に関し、更に
詳しくは一般式
(式中、Yはオルト位に弗素原子を置換分として有する
か有しないフェニル基を示し、Gはヒドロキシ低級アル
キル基を示し、Qはハロゲン原子を示す。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a novel pharmaceutical compound and a method for producing the same, and more specifically, the present invention relates to a novel pharmaceutical compound and a method for producing the same. It represents a hydroxy lower alkyl group, and Q represents a halogen atom.
)を有する2−アミノアセトアミド−α−フェニルベン
ジリデンアミノアルカノール誘導体の製法に関する。) A method for producing a 2-aminoacetamido-α-phenylbenzylidene aminoalkanol derivative having the following.
上記一般式(I)において、Gに含まれるヒドロキシ低
級アルキル基としては炭素数1乃至6の直鎖状若しくは
有枝鎖状のヒドロキシ低級アルキル基、例えばヒドロキ
シメチル、2−ヒドロキシエチル、1−ヒドロキシエチ
ル、3−ヒドロキシプロピル、2−ヒドロキシプロピル
、1−ヒドロキシプロピル、1−メチル−2−ヒドロキ
シエチル、■−メチルー1−ヒドロキシエチル、4−ヒ
ドロキシ−n−ブチル、3−ヒドロキシ−n−ブチル、
2−ヒドロキシ−n−ブチル、2−ヒドロキシメチル−
n−7’口ピル、5−ヒI−’0キシーn−ペンチル、
3−ヒドロキシメチル−n−ブチル、2−ヒドロキシメ
チル−n−ブチル、6−ヒドロキシ−n−ヘキシル、2
−ヒドロキシ−n−ヘキシル、2−ヒドロキシメチル−
n−ペンチル等があげられる。In the above general formula (I), the hydroxy lower alkyl group contained in G is a linear or branched hydroxy lower alkyl group having 1 to 6 carbon atoms, such as hydroxymethyl, 2-hydroxyethyl, 1-hydroxy Ethyl, 3-hydroxypropyl, 2-hydroxypropyl, 1-hydroxypropyl, 1-methyl-2-hydroxyethyl, ■-methyl-1-hydroxyethyl, 4-hydroxy-n-butyl, 3-hydroxy-n-butyl,
2-hydroxy-n-butyl, 2-hydroxymethyl-
n-7'pill, 5-hyI-'0xy n-pentyl,
3-hydroxymethyl-n-butyl, 2-hydroxymethyl-n-butyl, 6-hydroxy-n-hexyl, 2
-Hydroxy-n-hexyl, 2-hydroxymethyl-
Examples include n-pentyl.
Qに含まれるハロゲン原子としては塩素、臭素、沃素、
弗素である。Halogen atoms contained in Q include chlorine, bromine, iodine,
It is fluorine.
本発明の方法によって得られる前記一般式(1)を有す
る化合物は、いずれも新規な化合物であり、中枢神経系
の抑制作用を有し、優れたマイナートランキライザー作
用を有する医薬として有用な化合物である。The compounds having the general formula (1) obtained by the method of the present invention are all novel compounds, and are useful compounds as medicines that have central nervous system depressant action and excellent minor tranquilizer action. .
前記一般E(I)を有する化合物のうち、優れた効果を
有する一般式
(式中、YおよびQは前述したものと同意義を有し、A
は炭素数2乃至3の低級アルキレン基例えばエチレン、
トリメチレン、プロピレンである。Among the compounds having the general E(I), the general formula (wherein Y and Q have the same meanings as above, and A
is a lower alkylene group having 2 to 3 carbon atoms, such as ethylene,
trimethylene and propylene.
)を有する化合物であり、特に優れているのは一般式
(式中、Aは前述したものと同意義を有し、Q“は塩素
原子または臭素原子を示し、Rは水素原子または弗素原
子を示す。), and particularly excellent are compounds having the general formula (wherein A has the same meaning as above, Q" represents a chlorine atom or a bromine atom, and R represents a hydrogen atom or a fluorine atom. show.
)を有する化合物である。本発明の方法によって得られ
る化合物を投与する場合には、経口的投与あるいは非経
口的投与のいずれでもよく、例えば錠剤、カプセル剤、
散剤、顆粒剤、シロップ剤等による経口的投与、溶液若
しくは懸濁液としての注射剤または坐剤等による非経口
的投与があげられる。). When administering the compound obtained by the method of the present invention, it may be administered either orally or parenterally, for example in tablets, capsules, etc.
Examples include oral administration in the form of powders, granules, syrups, etc., parenteral administration in the form of injections as solutions or suspensions, suppositories, etc.
投与量は症状、年令、体重等によっても異なるが、通常
成人の場合的0.05乃至101n9/kg体重/日を
1回まタハ数回に分けて与えることができる。The dosage varies depending on symptoms, age, body weight, etc., but in general, for adults, 0.05 to 101n9/kg body weight/day can be given once or divided into several doses.
本発明の方法によれば、前記一般4I)を有する化合物
は、一般式
(式中、Y、GおよびQは前述したものと同意義を有す
る。According to the method of the present invention, the compound having the general formula 4I) is a compound having the general formula (wherein Y, G and Q have the same meanings as defined above).
)を有する2−アミノ−α−フェニルベンジリデンアミ
ノアルカノール化合物を一般式%式%)
(式中、Zは水素原子あるいはジクロロアセチル基、ト
リクロロアセチル基若しくはトリフルオロアセチル基の
ような容易に加水分解を受けて除去し得るアミン基の保
護基を示す。2-amino-α-phenylbenzylidene aminoalkanol compound having the general formula %) Indicates a protecting group for an amine group that can be removed by receiving the amine.
)を有するグリシンまたはその反応性誘導体と反応させ
ることによって一般式
がアミン基の保護基である化合物の場合にはこれを加水
分解することによって得ることができる。) can be obtained by hydrolyzing a compound whose general formula is a protecting group for an amine group by reacting it with glycine or a reactive derivative thereof.
なお前記一般式(IV)を有する化合物は、互変異性体
として一般式
(式中、YおよびQは前述したものと同意義を有りし、
Dは低級アルキレン基を示す。Note that the compound having the general formula (IV) has the general formula (wherein Y and Q have the same meanings as above,
D represents a lower alkylene group.
)で示される状態の化合物を含む場合もあり、その化合
物の存在する周囲の条件によって(IV)、(IV’)
75i平衡混合物の状態で存在することもある。), depending on the surrounding conditions where the compound exists, (IV), (IV')
75i may also exist in the form of an equilibrium mixture.
本発明の方法において、前記一般式側を有する」化合物
と前記一般式間を有する化合物の反応性誘導体とを反応
させる場合に、使用される前記一般式(ト)を有する化
合物の反応性誘導体としては例えば酸クロリド、酸ブ節
ミドなどの酸ハロゲン化合物:フェニル酢酸などとの混
酸無水物:酸アジド:」メチルエステル、エチルエステ
ルのようなアルキルエステル、P−ニトロフェニルエス
テルのヨウなアリールエステルなどのエステル類:アセ
トアミド、プロピオンアミドなどとの混酸イミド等をあ
げることができるがこれらの反応性誘導体に特:に限定
されるものではない。In the method of the present invention, when the compound having the above general formula is reacted with the reactive derivative of the compound having the above general formula, the reactive derivative of the compound having the general formula (g) used is For example, acid halogen compounds such as acid chloride and acid bindamide; mixed acid anhydrides with phenylacetic acid, etc.; acid azides: alkyl esters such as methyl esters and ethyl esters; Esters: Mixed acid imides with acetamide, propionamide, etc. can be mentioned, but the invention is not limited to these reactive derivatives.
また前記一般式(IV)を有する化合物を縮合剤の存在
下で前記一般式間を有する化合物と反応させる場合に、
使用される縮合剤としては例えばN、N’−ジシクロへ
キシルカルボジイミド、1−(3−ジメチルアミノプロ
ピ。Further, when the compound having the general formula (IV) is reacted with the compound having the general formula (IV) in the presence of a condensing agent,
Condensing agents used include, for example, N,N'-dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl).
ル)−3−エチルカルボジイミド塩酸塩、1−シクロへ
キシル−5−(2−モルホリノエチル)カルボジイミド
、■−シクロへキシル−3−(N−メチル−2−モルホ
リニウムエチル)カルボジイミドのようなN、 N’−
ジ置換カルボジイミド類二N、 N’−カルボニルジイ
ミダゾール、ジ−α−ピリジルカルボネート、5181
−カルボニルジ(α−チオピリジン)、N、 N’−カ
ルボニルジ(1゜2.4−トリアゾリド)、N1N’−
カルボニルジ(1,2,3−トリアゾリド)、N、N−
カルボニルジ(1,2,3,5−テトラゾリド)、N1
N1−カルボニルジ(3,5−ジメチルピラゾリドのよ
うなジ置換カルボニル化合物:クロル炭酸メチル、クロ
ル炭酸エチル、クロル炭酸イソブチルのようなりロル炭
酸エステル類:N1N’−チオニルジイミダゾール、亜
硫酸ジーP−ニトロフェニル、亜硫酸ジーP−ニトロフ
ェニルチオエステルのようなジ置換チオニル化合物:燐
酸トIJ −P−ニトロフェニル、ジイミダゾール−1
−ホスフィン酸モノエステル、ジエチルクロルホスファ
イト、テトラエチルピロホスファイトのような燐酸化合
物二N−エチルー5−フェニルイソオキサゾリウム−3
1−スルホン酸塩のようなウッドワード試薬:エトキシ
アセチレン、メチルエチニルジエチルアミン、エチルエ
チニルジエチルアミン、フロビルエチニルジエチルアミ
ン、ブチルエチニルジエチルアミンのようなアセチレン
化合物ニトリクロルアセトニトリル、N1N−ジエチル
シアナミド、N1N−ジフェニルシアナミド、N1N−
ジベンジルシアナミド、ジフェニルケテン−P−1−リ
ルイミンのような窒素化合物ニトリフルオル酢酸P−ニ
トロフェニル、トリフルオル酢酸ペンタクロルフェニル
のようなトリフルオル酢酸エステル類:フェニルスルホ
ニルクロリドのような71.1−ルスルホニルクロリド
類ニジヒドロピランのような不飽和複素環化合物:N−
カルボニルグリシンエチルエステルのようなN−カルボ
ニルアミノ酸エステル化合物ニジフェニルケテンのよう
なケテン類:3−ニトロアセトフェノンオキシムのよう
なオキシムおよびヒドロキシルアミン類:N−ベンジル
オキシカルボニルオキサブリジノン、N−1シルオキサ
ゾリジノンのようなN−アシルオキサゾリジノン類ニト
リフェニルホスフィン−2,2−ジピリジルジスルフィ
ド、トリフェニルホスファイト−22+−ジピリジルジ
スルフィドのような三価の燐化合物−ジスルフィド化合
物:ホスファゾ化合物などを好適な縮合剤としてあげる
ことができるが、これらの縮合剤に特に限定されるもの
ではない。)-3-ethylcarbodiimide hydrochloride, 1-cyclohexyl-5-(2-morpholinoethyl)carbodiimide, ■-cyclohexyl-3-(N-methyl-2-morpholiniumethyl)carbodiimide. N, N'-
Disubstituted carbodiimides diN, N'-carbonyldiimidazole, di-α-pyridyl carbonate, 5181
-carbonyldi(α-thiopyridine), N, N'-carbonyldi(1°2.4-triazolide), N1N'-
Carbonyl di(1,2,3-triazolide), N, N-
Carbonyl di(1,2,3,5-tetrazolide), N1
Disubstituted carbonyl compounds such as N1-carbonyl di(3,5-dimethylpyrazolide): methyl chlorocarbonate, ethyl chlorocarbonate, and isobutyl chlorocarbonate; N1N'-thionyldiimidazole, di-P sulfite; -Disubstituted thionyl compounds such as nitrophenyl, di-P-nitrophenyl thioester sulfite: IJ phosphate -P-nitrophenyl, diimidazole-1
- Phosphate compounds such as phosphinate monoester, diethylchlorophosphite, tetraethylpyrophosphite, diN-ethyl-5-phenylisoxazolium-3
Woodward reagents such as 1-sulfonates: acetylene compounds such as ethoxyacetylene, methylethynyldiethylamine, ethylethynyldiethylamine, flobylethynyldiethylamine, butylethynyldiethylamine, nitrichloroacetonitrile, N1N-diethylcyanamide, N1N-diphenylcyanamide, N1N-
Nitrogen compounds such as dibenzyl cyanamide and diphenylketene-P-1-lylimine Trifluoroacetic acid esters such as P-nitrophenyl nitrifluoroacetate and pentachlorphenyl trifluoroacetate: 71.1-lsulfonyl chloride such as phenylsulfonyl chloride Unsaturated heterocyclic compounds such as dihydropyran: N-
N-carbonyl amino acid ester compounds such as carbonylglycine ethyl ester Ketenes such as nidiphenyl ketene: Oximes and hydroxylamines such as 3-nitroacetophenone oxime: N-benzyloxycarbonyloxabridinone, N-1 siloxazolidinone Suitable condensing agents include N-acyloxazolidinones such as nitriphenylphosphine-2,2-dipyridyl disulfide, trivalent phosphorus compounds such as triphenylphosphine-22+-dipyridyl disulfide, disulfide compounds: phosphazo compounds, etc. However, these condensing agents are not particularly limited.
一般(こ酸アミドの製造法として知られる方法は本発明
の製造法として適用することが可能である。Generally known methods for producing phosphoric acid amide can be applied as the production method of the present invention.
本発明の方法を実施するに当って、反応は溶剤の存在下
または不存在下で行なわれる。In carrying out the process of the invention, the reaction is carried out in the presence or absence of a solvent.
反応を円滑に行なうには溶剤を使用する方が好ましく、
使用される溶剤としては反応に関与しない溶剤なら特に
限定はなく例えばメタノール、エタノール、インプロパ
ツールのような低級アルカノール類ニジエチルエーテル
、テトラヒドロフラン、ジオキサンのようなエーテル類
:クロロポルム、ジクロルメタン、ジクロルエタンのよ
うなハロゲン化炭化水素類:ベンゼン、トルエン、キシ
レンのような芳香族炭化水素類:酢酸エチル、プロピオ
ン酸メチルのような低級カルボン酸エステル類ニアセト
ニトリルのようなニトリル類ニジメチルホルムアミドの
ようなジアルキルホルムアミド類ニジメチルスルホキシ
ドのようなジアルキルスルホキシド類:ピリジン、ピコ
リン、ルチジン、キノリン、イソキノリン、コリジン、
N−メチルピペリジン、N−メチルモルホリンのような
異項環化合物ニトリエチルアミン、トリーローブチルア
ミンのような第三級アミン類等をあげることができる。It is preferable to use a solvent to facilitate the reaction.
The solvent to be used is not particularly limited as long as it does not participate in the reaction; for example, lower alkanols such as methanol, ethanol, and impropatol; ethers such as diethyl ether, tetrahydrofuran, and dioxane; and chloroporum, dichloromethane, and dichloroethane. Halogenated hydrocarbons: Aromatic hydrocarbons such as benzene, toluene, and xylene: Lower carboxylic acid esters such as ethyl acetate and methyl propionate Nitriles such as acetonitrile Dialkylformamides such as dimethylformamide Dialkyl sulfoxides such as dimethyl sulfoxide: pyridine, picoline, lutidine, quinoline, isoquinoline, collidine,
Examples include heterocyclic compounds such as N-methylpiperidine and N-methylmorpholine, nitriethylamine, and tertiary amines such as trilobylamine.
特に好適な溶剤としては例えばベンゼン、テトラヒドロ
フラン、ジオキサン、アセトニトリル、ジクロルメタン
、ジメチルホルムアミド等をあげることができる。Particularly suitable solvents include benzene, tetrahydrofuran, dioxane, acetonitrile, dichloromethane, dimethylformamide, and the like.
また反応試斉茫して前記一般式(ト)を有する化合物の
反応性誘導体を用いる場合に、前記一般式(至)を有す
る化合物の反応性誘導体が例えば酸ハロゲン化合物、酸
アジドなどである場合は常法に従って塩基の存在下で好
適に行なわれる。In addition, when a reactive derivative of a compound having the general formula (g) is used in a reaction test, the reactive derivative of the compound having the general formula (g) is, for example, an acid halide compound, an acid azide, etc. is preferably carried out in the presence of a base according to a conventional method.
使用される塩基としては例えばピリジン、ピコリン、ル
チジン、キノリン、イソキノリン、コリジン、N−メチ
ルピペリジン、N−メチルモルホリンのような異項環化
合物ニトリエチルアミン、トリーn−ブチルアミンのよ
うな第三級アミン類などの有機塩基類:炭酸すl−1)
ラム、炭酸カリウム炭酸カルシウムのようなアルカリ金
属およびアルカリ土類金属の炭酸塩:水酸化ナトIJウ
ム、水酸化カリウム、水酸化カルシウムのようなアルカ
リ金属およびアルカリ土類金属の水酸化物:炭酸水素ナ
トリウム、炭酸水素カリウム、炭酸水素カルシウムのよ
うなアルカリ金属およびアルカリ土類金属の重炭酸塩な
どの無機塩基類をあげることができるがこれらの塩基に
特に限定されるものではない。Examples of the bases used include heterocyclic compounds such as pyridine, picoline, lutidine, quinoline, isoquinoline, collidine, N-methylpiperidine, and N-methylmorpholine, and tertiary amines such as nitriethylamine and tri-n-butylamine. Organic bases such as carbonic acid l-1)
Alkali metal and alkaline earth metal carbonates such as rum, potassium carbonate Calcium carbonate: Alkali metal and alkaline earth metal hydroxides such as sodium hydroxide, potassium hydroxide, calcium hydroxide: hydrogen carbonate Examples include inorganic bases such as alkali metal and alkaline earth metal bicarbonates such as sodium, potassium hydrogen carbonate, and calcium hydrogen carbonate, but are not particularly limited to these bases.
これらの塩基のうち、有機塩基類は溶剤を兼ねることが
できる。Among these bases, organic bases can also serve as a solvent.
更に前記一般式(mを有する化合物を縮合剤の存在下で
前記一般式(至)を有する化合物と反応させるに際して
、使用される縮合剤の種類によって例えばピリジン、ピ
コリン、ルチジン、キノリン、インキノリン、コリジン
、N−メチルピペリジン、N−メチルモルホリンのよう
な異項環化合物ニトリエチルアミン、トリーn−ブチル
アミンのような第三級アミン類などの有機塩基類:炭酸
ナトリウム、炭酸カリウム、炭酸カルシウムのようなア
ルカリ金属およびアルカリ土類金属の炭酸塩:水酸化ナ
トリウム、水酸化カリウム、水酸化カルシウムのような
アルカリ金属およびアルカリ土類金属の水酸化物:炭酸
水素ナトリウム、炭酸水素カリウム、炭酸水素カルシウ
ムのようなアルカリ金属およびアルカリ土類金属の重炭
酸塩のような無機塩基類などの塩基の存在下で好適に行
なわれることがある。Furthermore, when the compound having the general formula (m) is reacted with the compound having the general formula (to) in the presence of a condensing agent, depending on the type of condensing agent used, for example, pyridine, picoline, lutidine, quinoline, inquinoline, Heterocyclic compounds such as collidine, N-methylpiperidine, and N-methylmorpholine Organic bases such as tertiary amines such as nitriethylamine and tri-n-butylamine; such as sodium carbonate, potassium carbonate, and calcium carbonate. Alkali metal and alkaline earth metal carbonates: such as sodium hydroxide, potassium hydroxide, calcium hydroxide Alkali metal and alkaline earth metal hydroxides: such as sodium bicarbonate, potassium bicarbonate, calcium bicarbonate It may be suitably carried out in the presence of a base such as an inorganic base such as an alkali metal or alkaline earth metal bicarbonate.
また前記一般式(W)を有する化合物を縮合剤の存在下
で前記一般式(ト)を有する化合物と反応させる場合に
、縮合剤が例えばN1■−ジシクロへキシルカルボジイ
ミドのようなN、 N’−ジ置換カルボジイミド類の場
合は、前記一般式(至)を有する化合物は例えば塩酸塩
、硫酸塩、硝酸塩のような塩の形で好適に用いられる。Further, when the compound having the general formula (W) is reacted with the compound having the general formula (g) in the presence of a condensing agent, the condensing agent may be N, N' such as N1■-dicyclohexylcarbodiimide, N' In the case of -disubstituted carbodiimides, the compound having the above general formula (-) is suitably used in the form of a salt such as a hydrochloride, a sulfate, or a nitrate.
反応温度には特に限定はないが、副反応を抑えるために
は比較的低温で行なうのが望ましく、通常好適には反応
当初は水冷下で行ない、次いで徐々に室温まで反応温度
を上げることによって行なわれる。Although there is no particular limitation on the reaction temperature, it is desirable to carry out the reaction at a relatively low temperature in order to suppress side reactions, and it is usually preferable to carry out the reaction under water cooling at the beginning, and then gradually raise the reaction temperature to room temperature. It will be done.
反応試剤のうち、前記一般式(至)を有する化合物の反
応性誘導体がエステル類の場合は、反応は室温以下では
充分に進行しないため通常は加熱によって好適に行なわ
れる。Among the reaction reagents, when the reactive derivative of the compound having the general formula (-) is an ester, the reaction does not proceed sufficiently below room temperature, so it is usually suitably carried out by heating.
反応に要する時間は主として原料化合物の種類、溶剤の
有無および種類、反応温度等によって異なる。The time required for the reaction differs mainly depending on the type of raw material compound, the presence or absence of a solvent, the type of solvent, the reaction temperature, etc.
反応終了後、前記一般式(Vllを有する目的化合物は
常法によって反応混合物から採取される。After the reaction is completed, the target compound having the general formula (Vll) is collected from the reaction mixture by a conventional method.
例えば反応終了後、反応混合物に適量の水または食塩水
を加え、さらに適当な有機溶剤を加えて抽出し、次いで
有機層を水洗し乾燥した後、有機層より溶剤を留去する
こと(こよって得られる。For example, after the reaction is complete, add an appropriate amount of water or saline to the reaction mixture, then add an appropriate organic solvent for extraction, wash the organic layer with water, dry it, and then distill off the solvent from the organic layer (thus, can get.
得られる目的化合物は更に再結晶法、カラムクロマトグ
ラフィー法等の常法に付して精製することによって目的
化合物の純品が得られる。The obtained target compound is further purified by conventional methods such as recrystallization and column chromatography to obtain a pure target compound.
次いで、前記一般式(■を有する化合物のうち、置換基
Zがジクロロアセチル基、トリクロロアセチル基若しく
はトリフルオロアセチル基のようなアミン基の保護基で
ある場合(こ、これらの保護基を加水分解して除去する
反応は水の存在下で加水分解試剤を用いて常法に従って
実施することができる。Next, in the compound having the general formula (■), when the substituent Z is a protecting group for an amine group such as a dichloroacetyl group, a trichloroacetyl group, or a trifluoroacetyl group (in this case, these protecting groups are hydrolyzed). The reaction for removal can be carried out in the presence of water using a hydrolysis reagent according to a conventional method.
使用される加水分解試剤としては例えば水酸化ナトリウ
ム、水酸化カリウムのようなアルカリ金属水酸化物:水
酸化カルシウム、水酸化バリウムのようなアルカリ土類
金属水酸化物:炭酸すトリウム、炭酸カリウムのような
アルカリ金属炭酸塩:炭酸水素ナトリウム、炭酸水素カ
リウムのようなアルカリ金属重炭酸塩:水酸化アンモニ
ウム等のアルカリ性加水分解試剤があげることができる
が、特に炭酸ナトリウム、炭酸カリウムのようなアルカ
リ金属炭酸塩が好適に使用される。Hydrolysis reagents used include, for example, alkali metal hydroxides such as sodium hydroxide and potassium hydroxide; alkaline earth metal hydroxides such as calcium hydroxide and barium hydroxide; thorium carbonate and potassium carbonate. Alkali metal carbonates such as sodium hydrogen carbonate and potassium hydrogen carbonate Alkali metal bicarbonates such as sodium hydrogen carbonate and potassium hydrogen carbonate include alkaline hydrolysis reagents such as ammonium hydroxide, but especially alkali metal carbonates such as sodium carbonate and potassium carbonate. Carbonates are preferably used.
反応は通常、溶剤の存在下で好適に行なわれる。The reaction is usually suitably carried out in the presence of a solvent.
使用される溶剤としては例えば水:メタノール、エタノ
ール、n−プロパツールのようなアルカノール類:テト
ラヒドロフラン、ジオキサンのようなエーテル類ニジメ
チルホルムアミドのようなジアルキルホルムアミド類等
の有機溶剤が好適な溶剤としてあげられ、特に水と有機
溶剤との混合溶剤が好適な溶剤として使用される。Suitable solvents include water, alkanols such as methanol, ethanol, and n-propanol, ethers such as tetrahydrofuran and dioxane, and organic solvents such as dialkylformamides such as dimethylformamide. In particular, a mixed solvent of water and an organic solvent is used as a suitable solvent.
反応温度には特に限定はないが、副反応を抑えるために
は比較的低温で行なうのが望ましく、通常好適には室温
付近で行なわれる。The reaction temperature is not particularly limited, but in order to suppress side reactions, it is desirable to carry out the reaction at a relatively low temperature, and it is usually preferably carried out at around room temperature.
反応に要する時間は主として原料化合物および溶剤の種
類、反応温度等によって異なるが、約8時間乃至20時
間である。The time required for the reaction varies mainly depending on the types of raw material compounds and solvents, reaction temperature, etc., but is approximately 8 to 20 hours.
反応終了後、前記一般式(I)を有する目的化合物は常
法に従って反応混合物から採取される。After completion of the reaction, the target compound having the general formula (I) is collected from the reaction mixture according to a conventional method.
例えば反応混合物より有機溶剤を留去し、次いで適当な
有機溶剤で抽出し、抽出液を水洗し、乾燥した後、抽出
液より溶剤を留去することによって得られる。For example, it can be obtained by distilling off the organic solvent from the reaction mixture, then extracting with a suitable organic solvent, washing the extract with water, drying, and then distilling off the solvent from the extract.
得られる目的化合物は必要ならば常法、例えば再結晶法
、カラムクロマトグラフィー法などによって精製するこ
とができる。The obtained target compound can be purified, if necessary, by conventional methods such as recrystallization, column chromatography, and the like.
次に実施例をあげて本発明の方法を更に具体的に説明す
る。Next, the method of the present invention will be explained in more detail with reference to Examples.
実施例 1
2−((2−アミノアセトアミド−5−ブロモ−α−(
2−フルオロフェニル)ベンジリゾ2アミノ)エタノー
ル
N、 N’−ジシクロへキシルカルボジイミド4.5g
をジメチルホルムアミド1001111に溶解した後、
水冷下で攪拌しながらグリシン塩酸塩2.2Iを水2、
2 mlに溶解した溶液を約30秒で加える。Example 1 2-((2-aminoacetamido-5-bromo-α-(
2-fluorophenyl) benzylizo 2-amino) ethanol N, N'-dicyclohexylcarbodiimide 4.5 g
After dissolving in dimethylformamide 1001111,
While stirring under water cooling, add 2.2 I of glycine hydrochloride to 2 liters of water,
Add the 2 ml solution in about 30 seconds.
反応混合物にただちに2−((2−アミノ−5−ブロモ
−α−(2−フルオロフェニル)ベンジリデンコアミノ
)エタノール3.4gをテトラヒドロフラン10m1f
ご溶解した溶液を滴下し、さらに室温で3時間攪拌する
。Immediately add 3.4 g of 2-((2-amino-5-bromo-α-(2-fluorophenyl)benzylidenecoamino)ethanol to the reaction mixture and add 10 ml of tetrahydrofuran.
The dissolved solution was added dropwise, and the mixture was further stirred at room temperature for 3 hours.
反応終了後、反応混合物に水11を加え、ベンゼン10
0m1で1回、さらに50m1で4回抽出する。After the reaction is complete, 11 parts of water is added to the reaction mixture, and 10 parts of benzene is added to the reaction mixture.
Extract once with 0 ml and then 4 times with 50 ml.
有機層を水洗し無水硫酸ナトリウムで乾燥後、有機層よ
り溶剤を留去すると黄色油状の残留物が得られる。After washing the organic layer with water and drying over anhydrous sodium sulfate, the solvent is distilled off from the organic layer to obtain a yellow oily residue.
得られる油状物をアルミナを用いるカラムクロマトグラ
フィーに付して精製し、次いでベンゼン−n−ヘキサン
より再結晶すると融点167〜168℃を有する目的化
合物2.39が得られる。The obtained oil is purified by column chromatography using alumina, and then recrystallized from benzene-n-hexane to obtain the target compound 2.39 having a melting point of 167-168°C.
実施例 2
2−〔(アミノアセトアミド−5−ブロモ−α−フェニ
ルベンジリデン)アミン〕エタノール2−(2−アミノ
−5−ブロモ−α−フェニルベンジリデンアミン)エタ
ノール3,2gおよびトリクロロアセチルグリシン2.
6gをジクロルメタン50m1に溶解した後、0℃でN
、 N’−ジシクロへキシルカルボジイミド2.5gを
加えて、徐々に室温にもどし3時間攪拌する。Example 2 2-[(aminoacetamido-5-bromo-α-phenylbenzylidene)amine]ethanol 2-(2-amino-5-bromo-α-phenylbenzylideneamine)ethanol 3.2 g and trichloroacetylglycine 2.
After dissolving 6 g in 50 ml of dichloromethane, N
, 2.5 g of N'-dicyclohexylcarbodiimide was added, and the mixture was gradually warmed to room temperature and stirred for 3 hours.
反応終了後、反応混合物より析出した沈澱を炉去し、ろ
液より溶剤を留去すると融点175〜176℃を有する
結晶4.3gが得られる。After completion of the reaction, the precipitate precipitated from the reaction mixture is removed from the furnace, and the solvent is distilled off from the filtrate to obtain 4.3 g of crystals having a melting point of 175-176°C.
この結晶をメタノール80m1およびテトラヒドロフラ
ン80m1に溶解した後、炭酸ナトリウム4.Ogを水
80TILlに溶かした溶液を加えて、更に室温で一夜
攪拌する。After dissolving the crystals in 80 ml of methanol and 80 ml of tetrahydrofuran, 4.0 ml of sodium carbonate was added. A solution of Og dissolved in 80 TIL of water is added, and the mixture is further stirred at room temperature overnight.
反応終了後、反応混合物より溶剤を留去し、残留物をジ
クロルメタンで抽出し、抽出液を水洗し無水硫酸ナトリ
ウムで乾燥後、抽出液より溶剤を留去すると目的化合物
の結晶が得られる。After completion of the reaction, the solvent is distilled off from the reaction mixture, the residue is extracted with dichloromethane, the extract is washed with water and dried over anhydrous sodium sulfate, and the solvent is distilled off from the extract to obtain crystals of the target compound.
これを酢酸エチルより再結晶すると融点153〜154
°Cを有する目的化合物の結晶0.96gが得られる。When this is recrystallized from ethyl acetate, the melting point is 153-154.
0.96 g of crystals of the target compound with a temperature of .degree.
実施例 3
2−((2−アミノアセトアミド−5−クロロ−α−(
2−フルオロフェニル)ベンジリデンシアミン)エタノ
ール
N、 N’−ジシクロへキシルカルボジイミド4.5g
をジメチルホルムアミド100m1に溶解した後、水冷
下で攪拌しながらグリシン塩酸塩2.2gを水2.2m
右こ溶解した溶液を約30秒で加える。Example 3 2-((2-aminoacetamide-5-chloro-α-(
2-fluorophenyl) benzylidenecyamine) ethanol N, N'-dicyclohexylcarbodiimide 4.5 g
After dissolving in 100 ml of dimethylformamide, 2.2 g of glycine hydrochloride was added to 2.2 ml of water while stirring under water cooling.
Add the dissolved solution in about 30 seconds.
反応混合物をただちに2−((2−アミノ−5−クロロ
−α−(2−フルオロフェニル)ベンジ’) テア)了
ミノ)エタノール3.2gをテトラヒドロフラン10T
llに溶解した溶液を滴下し、さらに室温で3時間攪拌
する。The reaction mixture was immediately mixed with 3.2 g of 2-((2-amino-5-chloro-α-(2-fluorophenyl)benzi') ethanol) and 10 T of tetrahydrofuran.
A solution dissolved in 1 ml was added dropwise, and the mixture was further stirred at room temperature for 3 hours.
反応終了後、反応混合物を以下、実施例1と同様に処理
、精製すると融点128〜132℃で有する目的化合物
1.7gが得られる。After the reaction is completed, the reaction mixture is treated and purified in the same manner as in Example 1 to obtain 1.7 g of the target compound having a melting point of 128-132°C.
実施例 4
2−((2−アミノアセトアミド−5−クロロ−α−フ
ェニルベンジリデン)アミン〕プロパツール
N1N’−ジシクロへキシルカルボジイミド4.5gを
ジメチルホルムアミド100m1に溶解した後水冷下で
攪拌しながらグリシン塩酸塩2.2gを水2.2mlに
溶解した溶液を約30秒で加える。Example 4 After dissolving 4.5 g of 2-((2-aminoacetamido-5-chloro-α-phenylbenzylidene)amine) propatool N1N'-dicyclohexylcarbodiimide in 100 ml of dimethylformamide, glycine was added with stirring under water cooling. A solution of 2.2 g of hydrochloride dissolved in 2.2 ml of water is added in about 30 seconds.
反応混合物にただちに2<(2−アミノ−5−クロロ−
α−フェニルベンジリデン)アミノコプロパツール3.
3gをテトラヒドロフラン10m1に溶解した溶液を滴
下し、さらに室温で3時間攪拌する。Immediately add 2<(2-amino-5-chloro-
α-phenylbenzylidene) aminocopropatool3.
A solution of 3 g dissolved in 10 ml of tetrahydrofuran was added dropwise, and the mixture was further stirred at room temperature for 3 hours.
反応終了後、反応混合物を以下、実施例1と同様に処理
、精製すると融点168〜172℃を有する目的化合物
1.3gが得られる。After the reaction is completed, the reaction mixture is treated and purified in the same manner as in Example 1 to obtain 1.3 g of the target compound having a melting point of 168-172°C.
本発明の方法によって得られる化合物の薬理効果をマウ
スを対象として試験方法およびED5゜値をもって例示
すると以下の如くである。The pharmacological effects of the compounds obtained by the method of the present invention are illustrated below using test methods and ED5° values in mice.
(1)抗ビメグライド痙翠作用
検体経口投与1時間後にビメグライドの30119/k
gを皮下投与し、30分間にわたって痙窒の抑制作用を
調べる。(1) 30119/k of bimeglide 1 hour after oral administration of anti-bimeglide spasmodic effect test sample
g was administered subcutaneously, and its inhibitory effect on spasticity was examined over a period of 30 minutes.
(2)抗電撃痙窒作用
検体経口投与1時間後に電撃(100OV、12.5m
A 10.2秒)を両眼から与えて痙翠の抑制作用を調
べる。(2) Electric shock (100OV, 12.5m
A 10.2 seconds) is administered from both eyes to examine the suppressive effect on spasticity.
(3)麻酔増強作用
検体経口投与1時間後にチオベンクールの30m9/k
gを静脈内投与し、正向反射消失の持続時間がチオペン
クール単独投与群の2倍に延長される用量を算出する。(3) Anesthesia-enhancing effect 30 m9/k of thiobencur 1 hour after oral administration of the sample
g is administered intravenously, and the dose at which the duration of loss of righting reflex is extended twice as long as in the thiopencor alone administration group is calculated.
(4)ED5o値の算出
Li tchf 1eld Wilcoxon法(J
、 Ph−armacol、Exp、Therap、
96巻、99頁(1949年)〕によって算出する。(4) Calculation of ED5o value Li tchf 1eld Wilcoxon method (J
, Ph-armacol, Exp, Therap,
96, p. 99 (1949)].
〔薬理効果〕 ED5o値(m9/に9 p −o
)* 化合物名は実施例NO,をもって示す。[Pharmacological effect] ED5o value (m9/9p-o
) *Compound names are indicated with Example No.
** 比較化合物はクロルジアゼポキシドである。**The comparative compound is chlordiazepoxide.
Claims (1)
か有しないフェニル基を示し、Gはヒドロキシ低級アル
キル基を示し、Qはハロゲン原子を示ス。 )を有する2−アミ7−α−フェニルベンジリデンアミ
ノアルカノール化合物を式 %式% (式中、Zは水素原子あるいはアミノ基の保護基を示す
。 )を有するグリシンまたはその反応性誘導体き反応させ
て式 (式中、Y、G、、QおよびZは前述したものと同意義
を有する。 )を有する化合物とし、さらlこZがアミノ基の保護基
である化合物の場合にはこれを加水分解することを特徴
とする式 (式中、Y、GおよびQは前述したものと同意義を有す
る。 )を有する2−アミノアセトアミド−α−フェニルベン
ジリデンアミノアルカノール誘導体の製造法。[Claims] Formula 1 (wherein Y represents a phenyl group with or without a fluorine atom as a substituent at the ortho position, G represents a hydroxy lower alkyl group, and Q represents a halogen atom.) A 2-ami7-α-phenylbenzylidene aminoalkanol compound having the formula % (in the formula, Z represents a hydrogen atom or a protecting group for an amino group) is reacted with glycine or its reactive derivative having the formula %. (In the formula, Y, G, Q and Z have the same meanings as defined above.), and in the case of a compound where Z is a protecting group for an amino group, this is hydrolyzed. A method for producing a 2-aminoacetamido-α-phenylbenzylidene aminoalkanol derivative having the formula (wherein Y, G and Q have the same meanings as described above).
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP50008503A JPS5823382B2 (en) | 1975-01-20 | 1975-01-20 | 2-Aminoacetamide-alpha-phenylbenzylidene aminoalkanol |
US05/645,890 US4022832A (en) | 1975-01-20 | 1975-12-31 | 2-Aminoacetamido-α-phenylbenzylideneaminoalkanol derivatives and process for the preparation thereof |
GB228/76A GB1487036A (en) | 1975-01-20 | 1976-01-05 | Pharmaceutically useful 2-aminoacetoamido-alpha-phenylbenzylideneaminoalkanol derivatives |
MX001462U MX3116E (en) | 1975-01-20 | 1976-01-13 | PROCEDURE FOR THE PREPARATION OF DERIVATIVES OF 2 - AMINO - ACETAMIDO - ALFA - FENIL BENCIL IDEN AMINO ALCANOL |
FR7600786A FR2297617A1 (en) | 1975-01-20 | 1976-01-14 | 2-AMINOACETAMIDO- DERIVATIVES |
CA243,616A CA1046527A (en) | 1975-01-20 | 1976-01-15 | PHARMACEUTICALLY USEFUL 2-AMINOACETAMIDO-.alpha.-PHENYLBENZYLIDENEAMINOALKANOL DERIVATIVES |
BE163547A BE837605A (en) | 1975-01-20 | 1976-01-15 | 2-AMINOACETAMINDO- -PHENYLLENZYLIDENE AMINOALCANOLS DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATIONS |
PH17978A PH11765A (en) | 1975-01-20 | 1976-01-15 | 2-aminoacetamido-alpha-phenylbenzylidenneamino-alkanol derivatives and process for the preparation thereof |
NL7600511A NL7600511A (en) | 1975-01-20 | 1976-01-19 | PROCESS FOR THE PREPARATION OF 2-AMINO-ACEETAMI-DO- (ALPHA) -PHENYL-BENZYLIDES-AMINO ALKANOL COMPOUNDS AND THEIR USE FOR THE PREPARATION OF MEDICINAL PRODUCTS. |
SE7600480A SE413243B (en) | 1975-01-20 | 1976-01-19 | PROCEDURE FOR PREPARING CERTAIN PHARMACEUTICAL USED AMINOAL CHANOL DERIVATIVES |
DK18976*#A DK18976A (en) | 1975-01-20 | 1976-01-19 | PROCEDURE FOR THE PREPARATION OF 2-AMINOACETAMIDO-ALFA-PHENYLBENZYLIDENAMINOAL CHANNEL DERIVATIVES |
CH64876A CH601196A5 (en) | 1975-01-20 | 1976-01-20 | |
DE19762601792 DE2601792A1 (en) | 1975-01-20 | 1976-01-20 | 2-AMINOACETAMIDO-ALPHA-PHENYLBENZYLIDENAMINOALCANOL DERIVATIVES AND PROCESS FOR THEIR PRODUCTION |
ES444481A ES444481A1 (en) | 1975-01-20 | 1976-01-20 | 2-Aminoacetamido-{60 -phenylbenzylideneaminoalkanol derivatives and process for the preparation thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP50008503A JPS5823382B2 (en) | 1975-01-20 | 1975-01-20 | 2-Aminoacetamide-alpha-phenylbenzylidene aminoalkanol |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5186452A JPS5186452A (en) | 1976-07-29 |
JPS5823382B2 true JPS5823382B2 (en) | 1983-05-14 |
Family
ID=11694906
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50008503A Expired JPS5823382B2 (en) | 1975-01-20 | 1975-01-20 | 2-Aminoacetamide-alpha-phenylbenzylidene aminoalkanol |
Country Status (14)
Country | Link |
---|---|
US (1) | US4022832A (en) |
JP (1) | JPS5823382B2 (en) |
BE (1) | BE837605A (en) |
CA (1) | CA1046527A (en) |
CH (1) | CH601196A5 (en) |
DE (1) | DE2601792A1 (en) |
DK (1) | DK18976A (en) |
ES (1) | ES444481A1 (en) |
FR (1) | FR2297617A1 (en) |
GB (1) | GB1487036A (en) |
MX (1) | MX3116E (en) |
NL (1) | NL7600511A (en) |
PH (1) | PH11765A (en) |
SE (1) | SE413243B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03112213A (en) * | 1989-09-26 | 1991-05-13 | Rinnai Corp | Radio receiver to be incorporated |
JPH03216883A (en) * | 1990-01-23 | 1991-09-24 | Clarion Co Ltd | Display device for acoustic apparatus |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2436776A1 (en) * | 1978-09-25 | 1980-04-18 | Fabre Sa Pierre | NOVEL ORTHO CHLORO BENZOYL-2 CHLORO-4 GLYCYLANILIDE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS |
US4472435A (en) * | 1980-07-31 | 1984-09-18 | Hoffman-La Roche Inc. | Benzophenone derivatives useful in treating heart failure |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3136815A (en) * | 1959-12-10 | 1964-06-09 | Hoffmann La Roche | Amino substituted benzophenone oximes and derivatives thereof |
US3202699A (en) * | 1961-07-11 | 1965-08-24 | Hoffmann La Roche | Carbobenzoxyglycylamino-benzophenones |
US3657344A (en) * | 1968-10-17 | 1972-04-18 | Hoffmann La Roche | 2-aminoxy-2'-acyl-acetanilide |
US3755300A (en) * | 1968-10-24 | 1973-08-28 | Sankyo Co | Process for the preparation of benzodiazepine compounds |
-
1975
- 1975-01-20 JP JP50008503A patent/JPS5823382B2/en not_active Expired
- 1975-12-31 US US05/645,890 patent/US4022832A/en not_active Expired - Lifetime
-
1976
- 1976-01-05 GB GB228/76A patent/GB1487036A/en not_active Expired
- 1976-01-13 MX MX001462U patent/MX3116E/en unknown
- 1976-01-14 FR FR7600786A patent/FR2297617A1/en active Granted
- 1976-01-15 PH PH17978A patent/PH11765A/en unknown
- 1976-01-15 CA CA243,616A patent/CA1046527A/en not_active Expired
- 1976-01-15 BE BE163547A patent/BE837605A/en unknown
- 1976-01-19 NL NL7600511A patent/NL7600511A/en not_active Application Discontinuation
- 1976-01-19 DK DK18976*#A patent/DK18976A/en unknown
- 1976-01-19 SE SE7600480A patent/SE413243B/en unknown
- 1976-01-20 DE DE19762601792 patent/DE2601792A1/en not_active Withdrawn
- 1976-01-20 ES ES444481A patent/ES444481A1/en not_active Expired
- 1976-01-20 CH CH64876A patent/CH601196A5/xx not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03112213A (en) * | 1989-09-26 | 1991-05-13 | Rinnai Corp | Radio receiver to be incorporated |
JPH03216883A (en) * | 1990-01-23 | 1991-09-24 | Clarion Co Ltd | Display device for acoustic apparatus |
Also Published As
Publication number | Publication date |
---|---|
SE413243B (en) | 1980-05-12 |
ES444481A1 (en) | 1977-09-16 |
MX3116E (en) | 1980-04-21 |
CH601196A5 (en) | 1978-06-30 |
DK18976A (en) | 1976-07-21 |
PH11765A (en) | 1978-06-27 |
DE2601792A1 (en) | 1976-07-22 |
FR2297617A1 (en) | 1976-08-13 |
US4022832A (en) | 1977-05-10 |
GB1487036A (en) | 1977-09-28 |
NL7600511A (en) | 1976-07-22 |
SE7600480L (en) | 1976-07-21 |
BE837605A (en) | 1976-07-15 |
FR2297617B1 (en) | 1979-09-21 |
CA1046527A (en) | 1979-01-16 |
JPS5186452A (en) | 1976-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103254213A (en) | Preparation method of maytenin-like ester and composition used in method | |
HU214871B (en) | Process for producing pyrazolepyridine derivatives | |
HU186983B (en) | Process for preparing new 3-amino-5-pregnene derivatives and salts thereof | |
US2745875A (en) | Preparation of nu-acylamino-phenylpropane diols | |
JPS6053027B2 (en) | Tetrazole derivative | |
US4210660A (en) | Benzamide derivatives | |
JPS5823382B2 (en) | 2-Aminoacetamide-alpha-phenylbenzylidene aminoalkanol | |
US4081455A (en) | 6-Amino-2,2-dimethyl-3-cyanopenams | |
IE50176B1 (en) | Process for the production of phenylglycyl chloride hydrochlorides | |
JP3207017B2 (en) | Method for producing benzylsuccinic acid derivative and intermediate for producing the same | |
JP3489116B2 (en) | New synthetic intermediates and methods for producing aminopiperazine derivatives | |
US3910899A (en) | 7-(2-Aminomethylphenyl-acetamido)-3-{8 2-(5-hydroxymethyl-1,3,4-thiadiazolyl)-thiomethyl{9 -3-cephem-4-carboxylic acid | |
JP2886586B2 (en) | Novel guanidinobenzoic acid derivatives and their acid addition salts | |
JP3207018B2 (en) | Method for producing benzylsuccinic acid derivative and intermediate for producing the same | |
JPS6042235B2 (en) | 2-Aminocetamido-α-phenylbenzylidene aminoalkanol derivatives and central nervous system depressants containing the derivatives | |
KR790001555B1 (en) | Process for the preparation of 2-amino acetamido- phenylbenzlideneaminoalkanol derivatives | |
WO1998032736A1 (en) | Process for producing benzylsuccinic acid derivatives | |
IE58497B1 (en) | New process for the preparation of derivatives of 4h-1, 2,4-triazole, the new triazoles so obtained, their use as medicaments and the pharmaceutical compositions containing them | |
JPH06172288A (en) | New phenylalanine derivative or its salt | |
KR20010030637A (en) | New process for producing aminopiperazine derivatives | |
US3654267A (en) | Process for the resolution of racemic 3-succinyloxy - 5 -phenyl-1 3-dihydro-2h-1 4 - benzodiazepine - 2-one-derivatives into optical antipodes | |
US2517588A (en) | Process for manufacture of penaldic acids and their derivatives | |
US3435033A (en) | Indolizinone derivatives | |
CS195707B2 (en) | Method of producing novel n up 4-substituted derivatives of 1,3,4,5-tetrahydro-2h-1,4-benzodiazepine-2-one | |
JP2654848B2 (en) | Novel isoquinoline derivatives or acid addition salts thereof |